A detailed history of Black Rock Inc. transactions in Savara Inc stock. As of the latest transaction made, Black Rock Inc. holds 8,030,614 shares of SVRA stock, worth $23.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,030,614
Previous 7,241,815 10.89%
Holding current value
$23.6 Million
Previous $36.1 Million 10.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.66 - $5.34 $2.89 Million - $4.21 Million
788,799 Added 10.89%
8,030,614 $32.4 Million
Q1 2024

May 10, 2024

SELL
$4.19 - $5.59 $82,605 - $110,206
-19,715 Reduced 0.27%
7,241,815 $36.1 Million
Q4 2023

Feb 13, 2024

BUY
$3.18 - $4.9 $3.89 Million - $5.99 Million
1,221,803 Added 20.23%
7,261,530 $34.1 Million
Q3 2023

Nov 13, 2023

BUY
$2.97 - $3.88 $3.39 Million - $4.43 Million
1,141,151 Added 23.3%
6,039,727 $22.8 Million
Q2 2023

Aug 11, 2023

BUY
$1.69 - $3.24 $6.51 Million - $12.5 Million
3,854,198 Added 369.04%
4,898,576 $15.6 Million
Q1 2023

May 12, 2023

BUY
$1.6 - $2.82 $7,238 - $12,757
4,524 Added 0.44%
1,044,378 $2.04 Million
Q4 2022

Feb 13, 2023

BUY
$1.11 - $1.64 $7,082 - $10,464
6,381 Added 0.62%
1,039,854 $1.61 Million
Q3 2022

Nov 14, 2022

SELL
$1.36 - $1.88 $4,424 - $6,115
-3,253 Reduced 0.31%
1,033,473 $1.6 Million
Q2 2022

Aug 12, 2022

SELL
$1.1 - $1.58 $3,907 - $5,612
-3,552 Reduced 0.34%
1,036,726 $1.58 Million
Q1 2022

May 12, 2022

SELL
$1.05 - $1.36 $8,364 - $10,833
-7,966 Reduced 0.76%
1,040,278 $1.36 Million
Q4 2021

Feb 10, 2022

BUY
$1.04 - $1.34 $2,548 - $3,283
2,450 Added 0.23%
1,048,244 $1.3 Million
Q3 2021

Nov 09, 2021

SELL
$1.18 - $1.64 $3,352 - $4,659
-2,841 Reduced 0.27%
1,045,794 $1.44 Million
Q2 2021

Aug 11, 2021

BUY
$1.51 - $2.29 $1.58 Million - $2.4 Million
1,048,635 New
1,048,635 $1.78 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $335M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.